Skip to main content
Smart Investors Daily
Axonics, Inc. logo

NASDAQ · AXNX

Axonics, Inc.

Healthcare · Medical - Devices

$0.93

Up+$0.10 (+10.61%)

Updated Nov 4, 2026, 9:01 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
3.63B
P/E ratio
527.22
Dividend yield
0.00%
52-week range
— – —
Volume
66.47K
Avg. volume
458.24K

Price performance · AXNX

AXNX price history

1M range · 16 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

AXNX closed at $0.93 after 16 trading sessions, up 31.15% for the selected period.

Last close
$0.93
Period change
+31.15%
Period low
$0.51
Period high
$1.23
Daily close
View OHLC price history
AXNX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$0.9411$1.02$0.9261$0.931266.47K
Nov 2, 2026$1.09$1.09$1.00$1.0067.11K
Oct 30, 2026$1.07$1.10$1.00$1.06101.33K
Oct 29, 2026$0.94$1.125$0.8749$1.03461.49K
Oct 28, 2026$0.752$1.25$0.71$0.946.87M
Oct 27, 2026$0.68$0.8378$0.68$0.8001114.94K
Oct 26, 2026$0.9697$0.9697$0.7104$0.76237.98K
Oct 23, 2026$1.11$1.11$1.00$1.0192.88K
Oct 22, 2026$1.16$1.20$1.02$1.13109.8K
Oct 21, 2026$1.0403$1.125$1.0262$1.099855.45K
Oct 20, 2026$1.0975$1.2575$1.0133$1.072596.27K
Oct 19, 2026$1.2533$1.3158$1.2075$1.225328.9K
Oct 16, 2026$1.2137$1.3167$1.178$1.17830.91K
Oct 15, 2026$0.50$0.5554$0.467$0.5128309.14K
Oct 14, 2026$0.71$0.71$0.4564$0.5925601.72K
Oct 13, 2026$0.804$0.845$0.70$0.71557.89K

Latest AXNX news

The latest Smart Investors Daily articles mentioning AXNX.

AXNX research

Overview

Company profile and research snapshot.

Company profile

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$71.00
Implied upside
—
Analysts
—
AXNX recent ratings
DateFirmRatingTarget
Nov 8, 2024NeedhamHold—
Aug 5, 2024NeedhamHold—
May 6, 2024NeedhamHold—
Feb 29, 2024RBC CapitalSector Perform—
Jan 17, 2024NeedhamHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 20, 2026

Axonex AI Group Limited Announces 2-for-5 Reverse Stock Split

Hong Kong, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Axonex AI Group Limited (“Axonex” or the “Company”, NASDAQ: AXNX), a Hong Kong-based company with a strategic focus on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider, announces that it is implementing a reverse stock split of all of the Company’s issued and unissued shares, including the Class A ordinary shares with no par value (the “Class A Ordinary Shares”) and Class B ordinary shar

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.